WHO ICTRP trial
NILE
JPRN-jRCT2080224099 · Japan Primary Registries Network (JPRN) · Recruiting
Key facts
| Trial ID | JPRN-jRCT2080224099 |
|---|---|
| Public title | NILE |
| Scientific title | A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination With Standard of Care Chemotherapy and Durvalumab in Combination With Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone in Patients With… |
| Primary sponsor | AstraZeneca |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | 3 |
| Conditions | Unresectable Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer |
| Interventions | investigational material(s) Generic name etc : Durvalumab, Tremelimumab, Cisplatin + Gemcitabine, Carboplatin + Gemcitabine INN of investigational material : Therapeutic category code : 42- Antineoplastic agents Dosage and Administration… |
| Registration date | Oct 17, 2018 |
| Secondary IDs | JapicCTI-184160 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: